nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—migraine—Prednisone—psoriasis	0.481	1	CpDpCtD
Eletriptan—CYP2A6—Methoxsalen—psoriasis	0.0518	0.159	CbGbCtD
Eletriptan—CYP2A6—Prednisolone—psoriasis	0.0252	0.0775	CbGbCtD
Eletriptan—CYP2D6—Hydroxyurea—psoriasis	0.0178	0.0548	CbGbCtD
Eletriptan—CYP2A6—Dexamethasone—psoriasis	0.0149	0.0457	CbGbCtD
Eletriptan—CYP2C19—Cholecalciferol—psoriasis	0.0142	0.0436	CbGbCtD
Eletriptan—CYP3A4—Calcitriol—psoriasis	0.0133	0.041	CbGbCtD
Eletriptan—CYP2C9—Cholecalciferol—psoriasis	0.0118	0.0363	CbGbCtD
Eletriptan—CYP2D6—Cholecalciferol—psoriasis	0.0108	0.0332	CbGbCtD
Eletriptan—CYP3A4—Methoxsalen—psoriasis	0.0104	0.0319	CbGbCtD
Eletriptan—ABCB1—Mycophenolate mofetil—psoriasis	0.00994	0.0305	CbGbCtD
Eletriptan—CYP2C19—Prednisone—psoriasis	0.00985	0.0303	CbGbCtD
Eletriptan—CYP2C19—Cyclosporine—psoriasis	0.00934	0.0287	CbGbCtD
Eletriptan—ABCB1—Betamethasone—psoriasis	0.00853	0.0262	CbGbCtD
Eletriptan—ABCB1—Prednisolone—psoriasis	0.00841	0.0258	CbGbCtD
Eletriptan—ABCB1—Hydrocortisone—psoriasis	0.00798	0.0245	CbGbCtD
Eletriptan—ABCB1—Prednisone—psoriasis	0.00795	0.0244	CbGbCtD
Eletriptan—CYP2C9—Cyclosporine—psoriasis	0.00776	0.0238	CbGbCtD
Eletriptan—ABCB1—Cyclosporine—psoriasis	0.00753	0.0231	CbGbCtD
Eletriptan—CYP2D6—Cyclosporine—psoriasis	0.0071	0.0218	CbGbCtD
Eletriptan—CYP3A4—Cholecalciferol—psoriasis	0.00687	0.0211	CbGbCtD
Eletriptan—CYP2C19—Dexamethasone—psoriasis	0.00615	0.0189	CbGbCtD
Eletriptan—CYP3A4—Mycophenolate mofetil—psoriasis	0.00595	0.0183	CbGbCtD
Eletriptan—CYP3A4—Triamcinolone—psoriasis	0.00595	0.0183	CbGbCtD
Eletriptan—CYP2C9—Dexamethasone—psoriasis	0.00511	0.0157	CbGbCtD
Eletriptan—CYP3A4—Betamethasone—psoriasis	0.00511	0.0157	CbGbCtD
Eletriptan—CYP3A4—Prednisolone—psoriasis	0.00504	0.0155	CbGbCtD
Eletriptan—ABCB1—Dexamethasone—psoriasis	0.00496	0.0152	CbGbCtD
Eletriptan—CYP3A4—Hydrocortisone—psoriasis	0.00478	0.0147	CbGbCtD
Eletriptan—CYP3A4—Prednisone—psoriasis	0.00476	0.0146	CbGbCtD
Eletriptan—CYP2D6—Dexamethasone—psoriasis	0.00467	0.0144	CbGbCtD
Eletriptan—CYP3A4—Cyclosporine—psoriasis	0.00451	0.0139	CbGbCtD
Eletriptan—ABCB1—Methotrexate—psoriasis	0.00399	0.0122	CbGbCtD
Eletriptan—CYP3A4—Dexamethasone—psoriasis	0.00297	0.00913	CbGbCtD
Eletriptan—Tachycardia—Triamcinolone—psoriasis	5.05e-05	0.000301	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Hydrocortisone—psoriasis	5.01e-05	0.000298	CcSEcCtD
Eletriptan—Hyperhidrosis—Triamcinolone—psoriasis	5e-05	0.000298	CcSEcCtD
Eletriptan—Convulsion—Betamethasone—psoriasis	4.99e-05	0.000297	CcSEcCtD
Eletriptan—Convulsion—Dexamethasone—psoriasis	4.99e-05	0.000297	CcSEcCtD
Eletriptan—Feeling abnormal—Mycophenolate mofetil—psoriasis	4.97e-05	0.000296	CcSEcCtD
Eletriptan—Insomnia—Hydrocortisone—psoriasis	4.97e-05	0.000296	CcSEcCtD
Eletriptan—Hypertension—Dexamethasone—psoriasis	4.97e-05	0.000296	CcSEcCtD
Eletriptan—Hypertension—Betamethasone—psoriasis	4.97e-05	0.000296	CcSEcCtD
Eletriptan—Paraesthesia—Hydrocortisone—psoriasis	4.94e-05	0.000294	CcSEcCtD
Eletriptan—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	4.94e-05	0.000294	CcSEcCtD
Eletriptan—Urticaria—Cyclosporine—psoriasis	4.91e-05	0.000292	CcSEcCtD
Eletriptan—Myalgia—Dexamethasone—psoriasis	4.9e-05	0.000292	CcSEcCtD
Eletriptan—Myalgia—Betamethasone—psoriasis	4.9e-05	0.000292	CcSEcCtD
Eletriptan—Abdominal pain—Cyclosporine—psoriasis	4.89e-05	0.000291	CcSEcCtD
Eletriptan—Body temperature increased—Cyclosporine—psoriasis	4.89e-05	0.000291	CcSEcCtD
Eletriptan—Anxiety—Dexamethasone—psoriasis	4.88e-05	0.000291	CcSEcCtD
Eletriptan—Anxiety—Betamethasone—psoriasis	4.88e-05	0.000291	CcSEcCtD
Eletriptan—Vomiting—Mycophenolic acid—psoriasis	4.86e-05	0.000289	CcSEcCtD
Eletriptan—Discomfort—Betamethasone—psoriasis	4.84e-05	0.000288	CcSEcCtD
Eletriptan—Discomfort—Dexamethasone—psoriasis	4.84e-05	0.000288	CcSEcCtD
Eletriptan—Dyspepsia—Hydrocortisone—psoriasis	4.84e-05	0.000288	CcSEcCtD
Eletriptan—Rash—Mycophenolic acid—psoriasis	4.82e-05	0.000287	CcSEcCtD
Eletriptan—Dermatitis—Mycophenolic acid—psoriasis	4.82e-05	0.000287	CcSEcCtD
Eletriptan—Pain—Prednisolone—psoriasis	4.81e-05	0.000287	CcSEcCtD
Eletriptan—Urticaria—Mycophenolate mofetil—psoriasis	4.79e-05	0.000285	CcSEcCtD
Eletriptan—Headache—Mycophenolic acid—psoriasis	4.79e-05	0.000285	CcSEcCtD
Eletriptan—Decreased appetite—Hydrocortisone—psoriasis	4.78e-05	0.000284	CcSEcCtD
Eletriptan—Pharyngitis—Methotrexate—psoriasis	4.78e-05	0.000284	CcSEcCtD
Eletriptan—Abdominal pain—Mycophenolate mofetil—psoriasis	4.77e-05	0.000284	CcSEcCtD
Eletriptan—Body temperature increased—Mycophenolate mofetil—psoriasis	4.77e-05	0.000284	CcSEcCtD
Eletriptan—Urinary tract disorder—Methotrexate—psoriasis	4.75e-05	0.000283	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.75e-05	0.000283	CcSEcCtD
Eletriptan—Fatigue—Hydrocortisone—psoriasis	4.74e-05	0.000282	CcSEcCtD
Eletriptan—Urethral disorder—Methotrexate—psoriasis	4.72e-05	0.000281	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.72e-05	0.000281	CcSEcCtD
Eletriptan—Pain—Hydrocortisone—psoriasis	4.7e-05	0.00028	CcSEcCtD
Eletriptan—Oedema—Dexamethasone—psoriasis	4.7e-05	0.00028	CcSEcCtD
Eletriptan—Oedema—Betamethasone—psoriasis	4.7e-05	0.00028	CcSEcCtD
Eletriptan—Insomnia—Triamcinolone—psoriasis	4.68e-05	0.000279	CcSEcCtD
Eletriptan—Ill-defined disorder—Prednisone—psoriasis	4.65e-05	0.000277	CcSEcCtD
Eletriptan—Paraesthesia—Triamcinolone—psoriasis	4.65e-05	0.000277	CcSEcCtD
Eletriptan—HTR1E—Signaling by GPCR—CCL20—psoriasis	4.64e-05	0.00184	CbGpPWpGaD
Eletriptan—Feeling abnormal—Prednisolone—psoriasis	4.64e-05	0.000276	CcSEcCtD
Eletriptan—Visual impairment—Methotrexate—psoriasis	4.64e-05	0.000276	CcSEcCtD
Eletriptan—Anaemia—Prednisone—psoriasis	4.63e-05	0.000276	CcSEcCtD
Eletriptan—Shock—Dexamethasone—psoriasis	4.62e-05	0.000275	CcSEcCtD
Eletriptan—Shock—Betamethasone—psoriasis	4.62e-05	0.000275	CcSEcCtD
Eletriptan—ABCB1—Allograft Rejection—HLA-B—psoriasis	4.62e-05	0.00183	CbGpPWpGaD
Eletriptan—Dyspnoea—Triamcinolone—psoriasis	4.62e-05	0.000275	CcSEcCtD
Eletriptan—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	4.61e-05	0.00183	CbGpPWpGaD
Eletriptan—Nervous system disorder—Betamethasone—psoriasis	4.61e-05	0.000274	CcSEcCtD
Eletriptan—Nervous system disorder—Dexamethasone—psoriasis	4.61e-05	0.000274	CcSEcCtD
Eletriptan—Agitation—Prednisone—psoriasis	4.61e-05	0.000274	CcSEcCtD
Eletriptan—Tachycardia—Betamethasone—psoriasis	4.58e-05	0.000273	CcSEcCtD
Eletriptan—Tachycardia—Dexamethasone—psoriasis	4.58e-05	0.000273	CcSEcCtD
Eletriptan—Angioedema—Prednisone—psoriasis	4.58e-05	0.000273	CcSEcCtD
Eletriptan—HTR1E—Signaling Pathways—TAGAP—psoriasis	4.58e-05	0.00182	CbGpPWpGaD
Eletriptan—HTR1A—GPCR ligand binding—CCL20—psoriasis	4.58e-05	0.00181	CbGpPWpGaD
Eletriptan—Hypersensitivity—Cyclosporine—psoriasis	4.56e-05	0.000271	CcSEcCtD
Eletriptan—Dyspepsia—Triamcinolone—psoriasis	4.56e-05	0.000271	CcSEcCtD
Eletriptan—Nausea—Mycophenolic acid—psoriasis	4.54e-05	0.00027	CcSEcCtD
Eletriptan—Hyperhidrosis—Dexamethasone—psoriasis	4.54e-05	0.00027	CcSEcCtD
Eletriptan—Hyperhidrosis—Betamethasone—psoriasis	4.54e-05	0.00027	CcSEcCtD
Eletriptan—Feeling abnormal—Hydrocortisone—psoriasis	4.53e-05	0.00027	CcSEcCtD
Eletriptan—HTR1A—Signaling by GPCR—HCAR2—psoriasis	4.52e-05	0.00179	CbGpPWpGaD
Eletriptan—Malaise—Prednisone—psoriasis	4.52e-05	0.000269	CcSEcCtD
Eletriptan—Vertigo—Prednisone—psoriasis	4.5e-05	0.000268	CcSEcCtD
Eletriptan—Gastrointestinal pain—Hydrocortisone—psoriasis	4.5e-05	0.000268	CcSEcCtD
Eletriptan—Syncope—Prednisone—psoriasis	4.5e-05	0.000268	CcSEcCtD
Eletriptan—Tinnitus—Methotrexate—psoriasis	4.49e-05	0.000267	CcSEcCtD
Eletriptan—Anorexia—Dexamethasone—psoriasis	4.48e-05	0.000266	CcSEcCtD
Eletriptan—Anorexia—Betamethasone—psoriasis	4.48e-05	0.000266	CcSEcCtD
Eletriptan—Urticaria—Prednisolone—psoriasis	4.47e-05	0.000266	CcSEcCtD
Eletriptan—Fatigue—Triamcinolone—psoriasis	4.46e-05	0.000266	CcSEcCtD
Eletriptan—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.45e-05	0.000265	CcSEcCtD
Eletriptan—Asthenia—Cyclosporine—psoriasis	4.44e-05	0.000264	CcSEcCtD
Eletriptan—Pain—Triamcinolone—psoriasis	4.43e-05	0.000263	CcSEcCtD
Eletriptan—Loss of consciousness—Prednisone—psoriasis	4.41e-05	0.000262	CcSEcCtD
Eletriptan—Hypotension—Betamethasone—psoriasis	4.39e-05	0.000261	CcSEcCtD
Eletriptan—Hypotension—Dexamethasone—psoriasis	4.39e-05	0.000261	CcSEcCtD
Eletriptan—Pruritus—Cyclosporine—psoriasis	4.38e-05	0.00026	CcSEcCtD
Eletriptan—HTR7—Circadian rythm related genes—NOS2—psoriasis	4.38e-05	0.00174	CbGpPWpGaD
Eletriptan—Urticaria—Hydrocortisone—psoriasis	4.37e-05	0.00026	CcSEcCtD
Eletriptan—Immune system disorder—Methotrexate—psoriasis	4.35e-05	0.000259	CcSEcCtD
Eletriptan—Body temperature increased—Hydrocortisone—psoriasis	4.35e-05	0.000259	CcSEcCtD
Eletriptan—Abdominal pain—Hydrocortisone—psoriasis	4.35e-05	0.000259	CcSEcCtD
Eletriptan—Convulsion—Prednisone—psoriasis	4.34e-05	0.000258	CcSEcCtD
Eletriptan—Asthenia—Mycophenolate mofetil—psoriasis	4.33e-05	0.000258	CcSEcCtD
Eletriptan—Hypertension—Prednisone—psoriasis	4.33e-05	0.000258	CcSEcCtD
Eletriptan—Chills—Methotrexate—psoriasis	4.32e-05	0.000257	CcSEcCtD
Eletriptan—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	4.3e-05	0.0017	CbGpPWpGaD
Eletriptan—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.28e-05	0.000255	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Betamethasone—psoriasis	4.28e-05	0.000255	CcSEcCtD
Eletriptan—HTR1F—G alpha (i) signalling events—CXCL8—psoriasis	4.28e-05	0.0017	CbGpPWpGaD
Eletriptan—ABCB1—Allograft Rejection—HLA-A—psoriasis	4.28e-05	0.0017	CbGpPWpGaD
Eletriptan—Pruritus—Mycophenolate mofetil—psoriasis	4.27e-05	0.000254	CcSEcCtD
Eletriptan—Myalgia—Prednisone—psoriasis	4.27e-05	0.000254	CcSEcCtD
Eletriptan—Arthralgia—Prednisone—psoriasis	4.27e-05	0.000254	CcSEcCtD
Eletriptan—Feeling abnormal—Triamcinolone—psoriasis	4.27e-05	0.000254	CcSEcCtD
Eletriptan—Anxiety—Prednisone—psoriasis	4.25e-05	0.000253	CcSEcCtD
Eletriptan—Alopecia—Methotrexate—psoriasis	4.25e-05	0.000253	CcSEcCtD
Eletriptan—Insomnia—Betamethasone—psoriasis	4.25e-05	0.000253	CcSEcCtD
Eletriptan—Insomnia—Dexamethasone—psoriasis	4.25e-05	0.000253	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.24e-05	0.000252	CcSEcCtD
Eletriptan—Diarrhoea—Cyclosporine—psoriasis	4.23e-05	0.000252	CcSEcCtD
Eletriptan—Paraesthesia—Dexamethasone—psoriasis	4.22e-05	0.000251	CcSEcCtD
Eletriptan—Paraesthesia—Betamethasone—psoriasis	4.22e-05	0.000251	CcSEcCtD
Eletriptan—Discomfort—Prednisone—psoriasis	4.22e-05	0.000251	CcSEcCtD
Eletriptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.21e-05	0.00167	CbGpPWpGaD
Eletriptan—Hypersensitivity—Prednisolone—psoriasis	4.15e-05	0.000247	CcSEcCtD
Eletriptan—Dyspepsia—Dexamethasone—psoriasis	4.14e-05	0.000246	CcSEcCtD
Eletriptan—Dyspepsia—Betamethasone—psoriasis	4.14e-05	0.000246	CcSEcCtD
Eletriptan—Diarrhoea—Mycophenolate mofetil—psoriasis	4.13e-05	0.000246	CcSEcCtD
Eletriptan—Urticaria—Triamcinolone—psoriasis	4.11e-05	0.000245	CcSEcCtD
Eletriptan—Dysgeusia—Methotrexate—psoriasis	4.1e-05	0.000244	CcSEcCtD
Eletriptan—Body temperature increased—Triamcinolone—psoriasis	4.09e-05	0.000244	CcSEcCtD
Eletriptan—Dizziness—Cyclosporine—psoriasis	4.09e-05	0.000243	CcSEcCtD
Eletriptan—HTR7—Circadian rythm related genes—PPARG—psoriasis	4.09e-05	0.00162	CbGpPWpGaD
Eletriptan—Oedema—Prednisone—psoriasis	4.09e-05	0.000243	CcSEcCtD
Eletriptan—Decreased appetite—Dexamethasone—psoriasis	4.08e-05	0.000243	CcSEcCtD
Eletriptan—Decreased appetite—Betamethasone—psoriasis	4.08e-05	0.000243	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Betamethasone—psoriasis	4.06e-05	0.000241	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Dexamethasone—psoriasis	4.06e-05	0.000241	CcSEcCtD
Eletriptan—Back pain—Methotrexate—psoriasis	4.05e-05	0.000241	CcSEcCtD
Eletriptan—Hypersensitivity—Hydrocortisone—psoriasis	4.05e-05	0.000241	CcSEcCtD
Eletriptan—Fatigue—Betamethasone—psoriasis	4.05e-05	0.000241	CcSEcCtD
Eletriptan—Fatigue—Dexamethasone—psoriasis	4.05e-05	0.000241	CcSEcCtD
Eletriptan—HTR1E—G alpha (i) signalling events—CXCL8—psoriasis	4.04e-05	0.0016	CbGpPWpGaD
Eletriptan—Shock—Prednisone—psoriasis	4.02e-05	0.00024	CcSEcCtD
Eletriptan—Pain—Betamethasone—psoriasis	4.02e-05	0.000239	CcSEcCtD
Eletriptan—Pain—Dexamethasone—psoriasis	4.02e-05	0.000239	CcSEcCtD
Eletriptan—Nervous system disorder—Prednisone—psoriasis	4.01e-05	0.000239	CcSEcCtD
Eletriptan—Tachycardia—Prednisone—psoriasis	3.99e-05	0.000238	CcSEcCtD
Eletriptan—Dizziness—Mycophenolate mofetil—psoriasis	3.99e-05	0.000238	CcSEcCtD
Eletriptan—Skin disorder—Prednisone—psoriasis	3.97e-05	0.000236	CcSEcCtD
Eletriptan—Hyperhidrosis—Prednisone—psoriasis	3.95e-05	0.000235	CcSEcCtD
Eletriptan—Asthenia—Hydrocortisone—psoriasis	3.94e-05	0.000235	CcSEcCtD
Eletriptan—Vomiting—Cyclosporine—psoriasis	3.93e-05	0.000234	CcSEcCtD
Eletriptan—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	3.91e-05	0.00155	CbGpPWpGaD
Eletriptan—Rash—Cyclosporine—psoriasis	3.9e-05	0.000232	CcSEcCtD
Eletriptan—Anorexia—Prednisone—psoriasis	3.9e-05	0.000232	CcSEcCtD
Eletriptan—Dermatitis—Cyclosporine—psoriasis	3.9e-05	0.000232	CcSEcCtD
Eletriptan—Pruritus—Hydrocortisone—psoriasis	3.89e-05	0.000232	CcSEcCtD
Eletriptan—Ill-defined disorder—Methotrexate—psoriasis	3.89e-05	0.000231	CcSEcCtD
Eletriptan—Headache—Cyclosporine—psoriasis	3.88e-05	0.000231	CcSEcCtD
Eletriptan—Anaemia—Methotrexate—psoriasis	3.87e-05	0.00023	CcSEcCtD
Eletriptan—Feeling abnormal—Dexamethasone—psoriasis	3.87e-05	0.00023	CcSEcCtD
Eletriptan—Feeling abnormal—Betamethasone—psoriasis	3.87e-05	0.00023	CcSEcCtD
Eletriptan—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	3.87e-05	0.00153	CbGpPWpGaD
Eletriptan—Gastrointestinal pain—Dexamethasone—psoriasis	3.84e-05	0.000229	CcSEcCtD
Eletriptan—Gastrointestinal pain—Betamethasone—psoriasis	3.84e-05	0.000229	CcSEcCtD
Eletriptan—Vomiting—Mycophenolate mofetil—psoriasis	3.84e-05	0.000228	CcSEcCtD
Eletriptan—Hypersensitivity—Triamcinolone—psoriasis	3.81e-05	0.000227	CcSEcCtD
Eletriptan—Rash—Mycophenolate mofetil—psoriasis	3.81e-05	0.000226	CcSEcCtD
Eletriptan—Dermatitis—Mycophenolate mofetil—psoriasis	3.8e-05	0.000226	CcSEcCtD
Eletriptan—Headache—Mycophenolate mofetil—psoriasis	3.78e-05	0.000225	CcSEcCtD
Eletriptan—Malaise—Methotrexate—psoriasis	3.78e-05	0.000225	CcSEcCtD
Eletriptan—Vertigo—Methotrexate—psoriasis	3.76e-05	0.000224	CcSEcCtD
Eletriptan—Diarrhoea—Hydrocortisone—psoriasis	3.76e-05	0.000224	CcSEcCtD
Eletriptan—Leukopenia—Methotrexate—psoriasis	3.75e-05	0.000223	CcSEcCtD
Eletriptan—Urticaria—Dexamethasone—psoriasis	3.73e-05	0.000222	CcSEcCtD
Eletriptan—Urticaria—Betamethasone—psoriasis	3.73e-05	0.000222	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Prednisone—psoriasis	3.73e-05	0.000222	CcSEcCtD
Eletriptan—Dizziness—Prednisolone—psoriasis	3.72e-05	0.000222	CcSEcCtD
Eletriptan—Asthenia—Triamcinolone—psoriasis	3.71e-05	0.000221	CcSEcCtD
Eletriptan—Body temperature increased—Dexamethasone—psoriasis	3.71e-05	0.000221	CcSEcCtD
Eletriptan—Abdominal pain—Betamethasone—psoriasis	3.71e-05	0.000221	CcSEcCtD
Eletriptan—Body temperature increased—Betamethasone—psoriasis	3.71e-05	0.000221	CcSEcCtD
Eletriptan—Abdominal pain—Dexamethasone—psoriasis	3.71e-05	0.000221	CcSEcCtD
Eletriptan—Insomnia—Prednisone—psoriasis	3.7e-05	0.00022	CcSEcCtD
Eletriptan—Nausea—Cyclosporine—psoriasis	3.67e-05	0.000219	CcSEcCtD
Eletriptan—Paraesthesia—Prednisone—psoriasis	3.67e-05	0.000219	CcSEcCtD
Eletriptan—Pruritus—Triamcinolone—psoriasis	3.66e-05	0.000218	CcSEcCtD
Eletriptan—Cough—Methotrexate—psoriasis	3.66e-05	0.000218	CcSEcCtD
Eletriptan—Dizziness—Hydrocortisone—psoriasis	3.64e-05	0.000216	CcSEcCtD
Eletriptan—Convulsion—Methotrexate—psoriasis	3.63e-05	0.000216	CcSEcCtD
Eletriptan—HTR7—Signaling Pathways—HCAR2—psoriasis	3.6e-05	0.00143	CbGpPWpGaD
Eletriptan—Dyspepsia—Prednisone—psoriasis	3.6e-05	0.000214	CcSEcCtD
Eletriptan—Nausea—Mycophenolate mofetil—psoriasis	3.58e-05	0.000213	CcSEcCtD
Eletriptan—HTR1D—Signaling Pathways—HCAR2—psoriasis	3.58e-05	0.00142	CbGpPWpGaD
Eletriptan—Arthralgia—Methotrexate—psoriasis	3.57e-05	0.000212	CcSEcCtD
Eletriptan—Myalgia—Methotrexate—psoriasis	3.57e-05	0.000212	CcSEcCtD
Eletriptan—Decreased appetite—Prednisone—psoriasis	3.56e-05	0.000212	CcSEcCtD
Eletriptan—Rash—Prednisolone—psoriasis	3.55e-05	0.000211	CcSEcCtD
Eletriptan—Dermatitis—Prednisolone—psoriasis	3.55e-05	0.000211	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.54e-05	0.000211	CcSEcCtD
Eletriptan—Fatigue—Prednisone—psoriasis	3.53e-05	0.00021	CcSEcCtD
Eletriptan—Headache—Prednisolone—psoriasis	3.53e-05	0.00021	CcSEcCtD
Eletriptan—Discomfort—Methotrexate—psoriasis	3.52e-05	0.00021	CcSEcCtD
Eletriptan—HTR1B—Signaling Pathways—HCAR2—psoriasis	3.51e-05	0.00139	CbGpPWpGaD
Eletriptan—Constipation—Prednisone—psoriasis	3.5e-05	0.000208	CcSEcCtD
Eletriptan—Vomiting—Hydrocortisone—psoriasis	3.5e-05	0.000208	CcSEcCtD
Eletriptan—HTR7—GPCR downstream signaling—CCL20—psoriasis	3.49e-05	0.00138	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—CCL20—psoriasis	3.47e-05	0.00137	CbGpPWpGaD
Eletriptan—Rash—Hydrocortisone—psoriasis	3.47e-05	0.000206	CcSEcCtD
Eletriptan—Dermatitis—Hydrocortisone—psoriasis	3.46e-05	0.000206	CcSEcCtD
Eletriptan—Confusional state—Methotrexate—psoriasis	3.45e-05	0.000205	CcSEcCtD
Eletriptan—Headache—Hydrocortisone—psoriasis	3.44e-05	0.000205	CcSEcCtD
Eletriptan—Dizziness—Triamcinolone—psoriasis	3.42e-05	0.000204	CcSEcCtD
Eletriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.4e-05	0.00135	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—CCL20—psoriasis	3.4e-05	0.00135	CbGpPWpGaD
Eletriptan—Feeling abnormal—Prednisone—psoriasis	3.37e-05	0.000201	CcSEcCtD
Eletriptan—Asthenia—Betamethasone—psoriasis	3.37e-05	0.000201	CcSEcCtD
Eletriptan—Asthenia—Dexamethasone—psoriasis	3.37e-05	0.000201	CcSEcCtD
Eletriptan—Nervous system disorder—Methotrexate—psoriasis	3.35e-05	0.0002	CcSEcCtD
Eletriptan—Gastrointestinal pain—Prednisone—psoriasis	3.35e-05	0.000199	CcSEcCtD
Eletriptan—Nausea—Prednisolone—psoriasis	3.34e-05	0.000199	CcSEcCtD
Eletriptan—Pruritus—Dexamethasone—psoriasis	3.32e-05	0.000198	CcSEcCtD
Eletriptan—Pruritus—Betamethasone—psoriasis	3.32e-05	0.000198	CcSEcCtD
Eletriptan—Skin disorder—Methotrexate—psoriasis	3.32e-05	0.000198	CcSEcCtD
Eletriptan—Hyperhidrosis—Methotrexate—psoriasis	3.31e-05	0.000197	CcSEcCtD
Eletriptan—HTR2B—Signaling Pathways—HCAR2—psoriasis	3.29e-05	0.00131	CbGpPWpGaD
Eletriptan—Vomiting—Triamcinolone—psoriasis	3.29e-05	0.000196	CcSEcCtD
Eletriptan—PTGS1—Metabolism—NDUFA5—psoriasis	3.28e-05	0.0013	CbGpPWpGaD
Eletriptan—Nausea—Hydrocortisone—psoriasis	3.27e-05	0.000194	CcSEcCtD
Eletriptan—Rash—Triamcinolone—psoriasis	3.26e-05	0.000194	CcSEcCtD
Eletriptan—Dermatitis—Triamcinolone—psoriasis	3.26e-05	0.000194	CcSEcCtD
Eletriptan—Anorexia—Methotrexate—psoriasis	3.26e-05	0.000194	CcSEcCtD
Eletriptan—Urticaria—Prednisone—psoriasis	3.25e-05	0.000193	CcSEcCtD
Eletriptan—Headache—Triamcinolone—psoriasis	3.24e-05	0.000193	CcSEcCtD
Eletriptan—Body temperature increased—Prednisone—psoriasis	3.23e-05	0.000192	CcSEcCtD
Eletriptan—Abdominal pain—Prednisone—psoriasis	3.23e-05	0.000192	CcSEcCtD
Eletriptan—Diarrhoea—Dexamethasone—psoriasis	3.21e-05	0.000191	CcSEcCtD
Eletriptan—Diarrhoea—Betamethasone—psoriasis	3.21e-05	0.000191	CcSEcCtD
Eletriptan—HTR1E—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.21e-05	0.00127	CbGpPWpGaD
Eletriptan—Hypotension—Methotrexate—psoriasis	3.19e-05	0.00019	CcSEcCtD
Eletriptan—HTR2B—GPCR downstream signaling—CCL20—psoriasis	3.19e-05	0.00126	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—CCL20—psoriasis	3.17e-05	0.00126	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—CCL20—psoriasis	3.15e-05	0.00125	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TAGAP—psoriasis	3.13e-05	0.00124	CbGpPWpGaD
Eletriptan—Musculoskeletal discomfort—Methotrexate—psoriasis	3.11e-05	0.000185	CcSEcCtD
Eletriptan—Dizziness—Dexamethasone—psoriasis	3.11e-05	0.000185	CcSEcCtD
Eletriptan—Dizziness—Betamethasone—psoriasis	3.11e-05	0.000185	CcSEcCtD
Eletriptan—HTR1D—Signaling Pathways—TAGAP—psoriasis	3.1e-05	0.00123	CbGpPWpGaD
Eletriptan—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.1e-05	0.00123	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—NDUFA5—psoriasis	3.1e-05	0.00123	CbGpPWpGaD
Eletriptan—Insomnia—Methotrexate—psoriasis	3.09e-05	0.000184	CcSEcCtD
Eletriptan—HTR1B—Signaling by GPCR—CCL20—psoriasis	3.08e-05	0.00122	CbGpPWpGaD
Eletriptan—Nausea—Triamcinolone—psoriasis	3.08e-05	0.000183	CcSEcCtD
Eletriptan—Paraesthesia—Methotrexate—psoriasis	3.07e-05	0.000183	CcSEcCtD
Eletriptan—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.06e-05	0.00121	CbGpPWpGaD
Eletriptan—Dyspnoea—Methotrexate—psoriasis	3.05e-05	0.000181	CcSEcCtD
Eletriptan—HTR1B—Signaling Pathways—TAGAP—psoriasis	3.04e-05	0.00121	CbGpPWpGaD
Eletriptan—Somnolence—Methotrexate—psoriasis	3.04e-05	0.000181	CcSEcCtD
Eletriptan—Hypersensitivity—Prednisone—psoriasis	3.01e-05	0.000179	CcSEcCtD
Eletriptan—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.01e-05	0.00119	CbGpPWpGaD
Eletriptan—Dyspepsia—Methotrexate—psoriasis	3.01e-05	0.000179	CcSEcCtD
Eletriptan—Vomiting—Betamethasone—psoriasis	2.99e-05	0.000178	CcSEcCtD
Eletriptan—Vomiting—Dexamethasone—psoriasis	2.99e-05	0.000178	CcSEcCtD
Eletriptan—Decreased appetite—Methotrexate—psoriasis	2.97e-05	0.000177	CcSEcCtD
Eletriptan—Rash—Betamethasone—psoriasis	2.96e-05	0.000176	CcSEcCtD
Eletriptan—Rash—Dexamethasone—psoriasis	2.96e-05	0.000176	CcSEcCtD
Eletriptan—Dermatitis—Betamethasone—psoriasis	2.96e-05	0.000176	CcSEcCtD
Eletriptan—Dermatitis—Dexamethasone—psoriasis	2.96e-05	0.000176	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Methotrexate—psoriasis	2.95e-05	0.000176	CcSEcCtD
Eletriptan—Fatigue—Methotrexate—psoriasis	2.95e-05	0.000175	CcSEcCtD
Eletriptan—Headache—Dexamethasone—psoriasis	2.94e-05	0.000175	CcSEcCtD
Eletriptan—Headache—Betamethasone—psoriasis	2.94e-05	0.000175	CcSEcCtD
Eletriptan—Asthenia—Prednisone—psoriasis	2.94e-05	0.000175	CcSEcCtD
Eletriptan—Pain—Methotrexate—psoriasis	2.92e-05	0.000174	CcSEcCtD
Eletriptan—HTR1F—Signaling Pathways—CCL20—psoriasis	2.91e-05	0.00115	CbGpPWpGaD
Eletriptan—HTR7—Circadian rythm related genes—JUN—psoriasis	2.9e-05	0.00115	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CCL20—psoriasis	2.9e-05	0.00115	CbGpPWpGaD
Eletriptan—Pruritus—Prednisone—psoriasis	2.89e-05	0.000172	CcSEcCtD
Eletriptan—HTR2B—Signaling Pathways—TAGAP—psoriasis	2.86e-05	0.00113	CbGpPWpGaD
Eletriptan—ABCB1—Allograft Rejection—IFNG—psoriasis	2.85e-05	0.00113	CbGpPWpGaD
Eletriptan—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.85e-05	0.00113	CbGpPWpGaD
Eletriptan—HTR1A—SIDS Susceptibility Pathways—CXCL8—psoriasis	2.83e-05	0.00112	CbGpPWpGaD
Eletriptan—Feeling abnormal—Methotrexate—psoriasis	2.82e-05	0.000168	CcSEcCtD
Eletriptan—Diarrhoea—Prednisone—psoriasis	2.8e-05	0.000167	CcSEcCtD
Eletriptan—Gastrointestinal pain—Methotrexate—psoriasis	2.8e-05	0.000166	CcSEcCtD
Eletriptan—Nausea—Dexamethasone—psoriasis	2.79e-05	0.000166	CcSEcCtD
Eletriptan—Nausea—Betamethasone—psoriasis	2.79e-05	0.000166	CcSEcCtD
Eletriptan—PTGS1—Metabolism—CYP2S1—psoriasis	2.79e-05	0.00111	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CCL20—psoriasis	2.74e-05	0.00109	CbGpPWpGaD
Eletriptan—HTR1D—G alpha (i) signalling events—CXCL8—psoriasis	2.74e-05	0.00108	CbGpPWpGaD
Eletriptan—Urticaria—Methotrexate—psoriasis	2.72e-05	0.000162	CcSEcCtD
Eletriptan—Dizziness—Prednisone—psoriasis	2.71e-05	0.000161	CcSEcCtD
Eletriptan—Abdominal pain—Methotrexate—psoriasis	2.7e-05	0.000161	CcSEcCtD
Eletriptan—Body temperature increased—Methotrexate—psoriasis	2.7e-05	0.000161	CcSEcCtD
Eletriptan—HTR1B—G alpha (i) signalling events—CXCL8—psoriasis	2.68e-05	0.00106	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—HCAR2—psoriasis	2.67e-05	0.00106	CbGpPWpGaD
Eletriptan—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.65e-05	0.00105	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—CYP2S1—psoriasis	2.64e-05	0.00105	CbGpPWpGaD
Eletriptan—HTR1A—SIDS Susceptibility Pathways—JUN—psoriasis	2.63e-05	0.00104	CbGpPWpGaD
Eletriptan—Vomiting—Prednisone—psoriasis	2.6e-05	0.000155	CcSEcCtD
Eletriptan—HTR1F—GPCR ligand binding—CXCL8—psoriasis	2.59e-05	0.00103	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—CCL20—psoriasis	2.59e-05	0.00103	CbGpPWpGaD
Eletriptan—Rash—Prednisone—psoriasis	2.58e-05	0.000154	CcSEcCtD
Eletriptan—Dermatitis—Prednisone—psoriasis	2.58e-05	0.000153	CcSEcCtD
Eletriptan—Headache—Prednisone—psoriasis	2.56e-05	0.000153	CcSEcCtD
Eletriptan—HTR1A—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.54e-05	0.00101	CbGpPWpGaD
Eletriptan—Hypersensitivity—Methotrexate—psoriasis	2.52e-05	0.00015	CcSEcCtD
Eletriptan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.49e-05	0.000987	CbGpPWpGaD
Eletriptan—Asthenia—Methotrexate—psoriasis	2.45e-05	0.000146	CcSEcCtD
Eletriptan—HTR1E—GPCR ligand binding—CXCL8—psoriasis	2.44e-05	0.000969	CbGpPWpGaD
Eletriptan—Nausea—Prednisone—psoriasis	2.43e-05	0.000145	CcSEcCtD
Eletriptan—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.43e-05	0.000963	CbGpPWpGaD
Eletriptan—Pruritus—Methotrexate—psoriasis	2.42e-05	0.000144	CcSEcCtD
Eletriptan—HTR1A—Signaling by GPCR—CCL20—psoriasis	2.35e-05	0.000931	CbGpPWpGaD
Eletriptan—Diarrhoea—Methotrexate—psoriasis	2.34e-05	0.000139	CcSEcCtD
Eletriptan—HTR1A—Signaling Pathways—TAGAP—psoriasis	2.32e-05	0.000918	CbGpPWpGaD
Eletriptan—HTR1A—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.3e-05	0.000912	CbGpPWpGaD
Eletriptan—Dizziness—Methotrexate—psoriasis	2.26e-05	0.000135	CcSEcCtD
Eletriptan—HTR7—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.19e-05	0.000868	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.19e-05	0.000866	CbGpPWpGaD
Eletriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.18e-05	0.000863	CbGpPWpGaD
Eletriptan—Vomiting—Methotrexate—psoriasis	2.17e-05	0.000129	CcSEcCtD
Eletriptan—Rash—Methotrexate—psoriasis	2.16e-05	0.000128	CcSEcCtD
Eletriptan—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.16e-05	0.000854	CbGpPWpGaD
Eletriptan—Dermatitis—Methotrexate—psoriasis	2.15e-05	0.000128	CcSEcCtD
Eletriptan—Headache—Methotrexate—psoriasis	2.14e-05	0.000127	CcSEcCtD
Eletriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.13e-05	0.000845	CbGpPWpGaD
Eletriptan—HTR1A—G alpha (i) signalling events—CXCL8—psoriasis	2.04e-05	0.000809	CbGpPWpGaD
Eletriptan—Nausea—Methotrexate—psoriasis	2.03e-05	0.000121	CcSEcCtD
Eletriptan—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2e-05	0.000793	CbGpPWpGaD
Eletriptan—HTR1A—SIDS Susceptibility Pathways—TNF—psoriasis	1.97e-05	0.000782	CbGpPWpGaD
Eletriptan—HTR7—Circadian rythm related genes—TP53—psoriasis	1.92e-05	0.000759	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—NDUFA5—psoriasis	1.89e-05	0.00075	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCL20—psoriasis	1.87e-05	0.000742	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCL20—psoriasis	1.86e-05	0.000737	CbGpPWpGaD
Eletriptan—ABCB1—Allograft Rejection—TNF—psoriasis	1.85e-05	0.000732	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—NDUFA5—psoriasis	1.85e-05	0.000732	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.84e-05	0.000728	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCL20—psoriasis	1.82e-05	0.000722	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.76e-05	0.000699	CbGpPWpGaD
Eletriptan—HTR7—Circadian rythm related genes—IL6—psoriasis	1.75e-05	0.000695	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—NDUFA5—psoriasis	1.74e-05	0.00069	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—NDUFA5—psoriasis	1.73e-05	0.000684	CbGpPWpGaD
Eletriptan—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.72e-05	0.00068	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCL20—psoriasis	1.71e-05	0.000678	CbGpPWpGaD
Eletriptan—HTR7—GPCR ligand binding—CXCL8—psoriasis	1.67e-05	0.000661	CbGpPWpGaD
Eletriptan—HTR1D—GPCR ligand binding—CXCL8—psoriasis	1.66e-05	0.000657	CbGpPWpGaD
Eletriptan—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.64e-05	0.000649	CbGpPWpGaD
Eletriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.62e-05	0.000643	CbGpPWpGaD
Eletriptan—HTR1B—GPCR ligand binding—CXCL8—psoriasis	1.62e-05	0.000643	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CYP2S1—psoriasis	1.61e-05	0.000638	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.61e-05	0.000638	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—SOCS1—psoriasis	1.6e-05	0.000635	CbGpPWpGaD
Eletriptan—HTR1A—SIDS Susceptibility Pathways—IL6—psoriasis	1.59e-05	0.000631	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CYP2S1—psoriasis	1.57e-05	0.000622	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—TYK2—psoriasis	1.53e-05	0.000605	CbGpPWpGaD
Eletriptan—HTR2B—GPCR ligand binding—CXCL8—psoriasis	1.52e-05	0.000604	CbGpPWpGaD
Eletriptan—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.52e-05	0.000602	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—SOCS1—psoriasis	1.51e-05	0.000599	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CYP2S1—psoriasis	1.48e-05	0.000587	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CYP2S1—psoriasis	1.47e-05	0.000582	CbGpPWpGaD
Eletriptan—HTR1F—GPCR downstream signaling—CXCL8—psoriasis	1.46e-05	0.00058	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.46e-05	0.00058	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—TYK2—psoriasis	1.44e-05	0.000571	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCL20—psoriasis	1.39e-05	0.00055	CbGpPWpGaD
Eletriptan—HTR1E—GPCR downstream signaling—CXCL8—psoriasis	1.38e-05	0.000548	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—CARM1—psoriasis	1.36e-05	0.00054	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—CXCL8—psoriasis	1.33e-05	0.000527	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—CARM1—psoriasis	1.29e-05	0.000511	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.27e-05	0.000505	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—CXCL8—psoriasis	1.25e-05	0.000497	CbGpPWpGaD
Eletriptan—HTR1A—GPCR ligand binding—CXCL8—psoriasis	1.24e-05	0.00049	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.22e-05	0.000483	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—LEP—psoriasis	1.18e-05	0.000469	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—APOE—psoriasis	1.18e-05	0.000469	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.17e-05	0.000465	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NDUFA5—psoriasis	1.14e-05	0.000451	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—LEP—psoriasis	1.11e-05	0.000442	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—APOE—psoriasis	1.11e-05	0.000442	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—NFKBIA—psoriasis	1.1e-05	0.000437	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.06e-05	0.000422	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—NFKBIA—psoriasis	1.04e-05	0.000412	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—SOCS1—psoriasis	1.03e-05	0.000409	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—SOCS1—psoriasis	1.02e-05	0.000406	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—SOCS1—psoriasis	1e-05	0.000398	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—TYK2—psoriasis	9.83e-06	0.00039	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—TYK2—psoriasis	9.77e-06	0.000387	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP2S1—psoriasis	9.67e-06	0.000384	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—TYK2—psoriasis	9.56e-06	0.000379	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—CXCL8—psoriasis	9.42e-06	0.000374	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—SOCS1—psoriasis	9.42e-06	0.000374	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—CXCL8—psoriasis	9.36e-06	0.000371	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—CXCL8—psoriasis	9.17e-06	0.000363	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	9.12e-06	0.000361	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TYK2—psoriasis	9.02e-06	0.000358	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—TYK2—psoriasis	8.98e-06	0.000356	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—CXCL8—psoriasis	8.61e-06	0.000341	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—CXCL8—psoriasis	8.56e-06	0.000339	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TYK2—psoriasis	8.51e-06	0.000337	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—CXCL8—psoriasis	8.5e-06	0.000337	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.43e-06	0.000334	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—CAT—psoriasis	8.38e-06	0.000332	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—CXCL8—psoriasis	8.33e-06	0.00033	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	8.04e-06	0.000319	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—CAT—psoriasis	7.93e-06	0.000314	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CARM1—psoriasis	7.86e-06	0.000311	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CXCL8—psoriasis	7.85e-06	0.000311	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CXCL8—psoriasis	7.82e-06	0.00031	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.69e-06	0.000305	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CARM1—psoriasis	7.67e-06	0.000304	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—SOCS1—psoriasis	7.64e-06	0.000303	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—LEP—psoriasis	7.61e-06	0.000302	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—APOE—psoriasis	7.61e-06	0.000302	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—LEP—psoriasis	7.56e-06	0.0003	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—APOE—psoriasis	7.56e-06	0.0003	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—IL6—psoriasis	7.47e-06	0.000296	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CXCL8—psoriasis	7.41e-06	0.000294	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—LEP—psoriasis	7.4e-06	0.000293	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—APOE—psoriasis	7.4e-06	0.000293	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.34e-06	0.000291	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—JUN—psoriasis	7.3e-06	0.00029	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—TYK2—psoriasis	7.28e-06	0.000289	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CARM1—psoriasis	7.23e-06	0.000286	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CARM1—psoriasis	7.16e-06	0.000284	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NFKBIA—psoriasis	7.09e-06	0.000281	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—IL6—psoriasis	7.05e-06	0.000279	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NFKBIA—psoriasis	7.04e-06	0.000279	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—NFKB1—psoriasis	7.03e-06	0.000279	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—CXCL8—psoriasis	6.98e-06	0.000277	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—LEP—psoriasis	6.95e-06	0.000276	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—APOE—psoriasis	6.95e-06	0.000276	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NFKBIA—psoriasis	6.9e-06	0.000273	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—JUN—psoriasis	6.89e-06	0.000273	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.7e-06	0.000265	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—NFKB1—psoriasis	6.63e-06	0.000263	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—APOE—psoriasis	6.51e-06	0.000258	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NFKBIA—psoriasis	6.48e-06	0.000257	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—VEGFA—psoriasis	6.38e-06	0.000253	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CXCL8—psoriasis	6.34e-06	0.000251	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—STAT3—psoriasis	6.32e-06	0.00025	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—APOE—psoriasis	6.16e-06	0.000244	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—VEGFA—psoriasis	6.02e-06	0.000239	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—STAT3—psoriasis	5.96e-06	0.000236	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TYK2—psoriasis	5.81e-06	0.00023	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TYK2—psoriasis	5.77e-06	0.000229	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PPARG—psoriasis	5.67e-06	0.000225	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TYK2—psoriasis	5.65e-06	0.000224	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—LEP—psoriasis	5.64e-06	0.000224	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—APOE—psoriasis	5.64e-06	0.000224	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PPARG—psoriasis	5.36e-06	0.000213	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TYK2—psoriasis	5.31e-06	0.00021	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NFKBIA—psoriasis	5.25e-06	0.000208	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CXCL8—psoriasis	5.06e-06	0.0002	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CXCL8—psoriasis	5.02e-06	0.000199	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CXCL8—psoriasis	4.92e-06	0.000195	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CAT—psoriasis	4.83e-06	0.000192	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TP53—psoriasis	4.82e-06	0.000191	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—IL6—psoriasis	4.81e-06	0.000191	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—IL6—psoriasis	4.78e-06	0.000189	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CARM1—psoriasis	4.72e-06	0.000187	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CAT—psoriasis	4.72e-06	0.000187	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—JUN—psoriasis	4.7e-06	0.000186	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—IL6—psoriasis	4.68e-06	0.000185	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—JUN—psoriasis	4.67e-06	0.000185	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CXCL8—psoriasis	4.62e-06	0.000183	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—JUN—psoriasis	4.57e-06	0.000181	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TP53—psoriasis	4.55e-06	0.00018	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NFKB1—psoriasis	4.52e-06	0.000179	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NFKB1—psoriasis	4.49e-06	0.000178	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CAT—psoriasis	4.44e-06	0.000176	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—IL6—psoriasis	4.41e-06	0.000175	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CAT—psoriasis	4.41e-06	0.000175	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NFKB1—psoriasis	4.4e-06	0.000174	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—IL6—psoriasis	4.39e-06	0.000174	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TYK2—psoriasis	4.3e-06	0.000171	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—JUN—psoriasis	4.3e-06	0.00017	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL6—psoriasis	4.16e-06	0.000165	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NFKB1—psoriasis	4.13e-06	0.000164	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—VEGFA—psoriasis	4.11e-06	0.000163	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—VEGFA—psoriasis	4.08e-06	0.000162	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—STAT3—psoriasis	4.07e-06	0.000161	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—STAT3—psoriasis	4.04e-06	0.00016	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—VEGFA—psoriasis	3.99e-06	0.000158	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—STAT3—psoriasis	3.96e-06	0.000157	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—APOE—psoriasis	3.75e-06	0.000149	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—VEGFA—psoriasis	3.75e-06	0.000149	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCL8—psoriasis	3.75e-06	0.000149	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—STAT3—psoriasis	3.72e-06	0.000147	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—APOE—psoriasis	3.66e-06	0.000145	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL6—psoriasis	3.56e-06	0.000141	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—JUN—psoriasis	3.48e-06	0.000138	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—APOE—psoriasis	3.45e-06	0.000137	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—APOE—psoriasis	3.42e-06	0.000136	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NFKB1—psoriasis	3.35e-06	0.000133	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PPARG—psoriasis	3.27e-06	0.00013	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PPARG—psoriasis	3.19e-06	0.000127	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TP53—psoriasis	3.1e-06	0.000123	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TP53—psoriasis	3.08e-06	0.000122	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—VEGFA—psoriasis	3.04e-06	0.000121	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TP53—psoriasis	3.02e-06	0.00012	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—STAT3—psoriasis	3.01e-06	0.000119	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PPARG—psoriasis	3.01e-06	0.000119	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PPARG—psoriasis	2.98e-06	0.000118	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CAT—psoriasis	2.91e-06	0.000115	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL6—psoriasis	2.84e-06	0.000113	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TP53—psoriasis	2.84e-06	0.000112	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL6—psoriasis	2.82e-06	0.000112	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL6—psoriasis	2.76e-06	0.00011	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL6—psoriasis	2.6e-06	0.000103	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TP53—psoriasis	2.3e-06	9.12e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—APOE—psoriasis	2.26e-06	8.95e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6—psoriasis	2.1e-06	8.34e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PPARG—psoriasis	1.97e-06	7.8e-05	CbGpPWpGaD
